Expert Review of Gastroenterology & Hepatology最新文献_第3页

EUS guided gastrojejunostomy: techniques and outcomes. EUS引导下的胃空肠吻合术：技术和结果。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-05-27 DOI: 10.1080/17474124.2025.2512168

Sachin Hosahally Jayanna, Surinder Singh Rana

{"title":"EUS guided gastrojejunostomy: techniques and outcomes.","authors":"Sachin Hosahally Jayanna, Surinder Singh Rana","doi":"10.1080/17474124.2025.2512168","DOIUrl":"10.1080/17474124.2025.2512168","url":null,"abstract":"Introduction: Surgical bypass, the traditional approach for managing gastric outlet obstruction (GOO), is effective but associated with increased morbidity and short-term complications. Enteral self-expanding metal stents (SEMS) provide a safe, effective, and minimally invasive alternative to surgical bypass, though they carry an increased risk of re-interventions due to stent blockage. Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) is a recently developed, novel minimally invasive procedure that serves as an alternative to enteral SEMS placement.Areas covered: We performed an electronic search in PubMed and included all the types of articles on EUS-GJ written in English language till February 2025. This review discusses both the technical details and outcomes of EUS-GJ.Expert opinion: EUS-GJ involves creating an anastomosis between the stomach and the small intestine using a lumen-apposing metal stent (LAMS). There are three basic techniques for performing EUS-GJ: the direct technique, the balloon-assisted technique, and the EPASS (EUS-guided double-balloon-occluded gastrojejunostomy bypass) technique. Among these, the free-hand direct approach is the most widely used due to its shorter procedure time and comparable technical outcomes to the other two techniques. Stent misdeployment is the most dreaded complication of EUS-GJ; however, fortunately, the majority of misdeployments can be successfully managed through rescue endoscopic methods.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-10"},"PeriodicalIF":3.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The position of anti-Tumor Necrosis Factor agents for the treatment of adult patients with Crohn's disease. 抗肿瘤坏死因子药物在成人克罗恩病治疗中的地位

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-05-26 DOI: 10.1080/17474124.2025.2511148

Stephen B Hanauer, Byong Duk Ye, Raymond K Cross, Silvio Danese, Geert D'Haens, Jinah Jung

{"title":"The position of anti-Tumor Necrosis Factor agents for the treatment of adult patients with Crohn's disease.","authors":"Stephen B Hanauer, Byong Duk Ye, Raymond K Cross, Silvio Danese, Geert D'Haens, Jinah Jung","doi":"10.1080/17474124.2025.2511148","DOIUrl":"https://doi.org/10.1080/17474124.2025.2511148","url":null,"abstract":"Introduction: Tumor Necrosis Factor α (TNF) is a significant systemic inflammatory cytokine in several immune-mediated inflammatory diseases (IMIDs) including inflammatory bowel disease (IBD, Crohn's disease (CD), and ulcerative colitis) and was the first target approved for biologic therapy in IBD.Areas covered: This article reviews the efficacy and safety of antiTNF agents for the treatment of CD including specific conditions (e.g. perianal fistula, prevention of post-operative recurrence), and practical approaches to managing antiTNF therapy (e.g. combination with immunosuppressants, early introduction of antiTNF treatment, and therapeutic drug monitoring (TDM)). This review is based on data from randomized controlled trials, real-world evidences and comparative studies gathered over the past 25 years.Expert opinion: Anti-TNF agents have revolutionized treatment of IBD and other IMIDs. Early introduction of treatment, concurrent use of immunomodulators, and TDM are associated with improved clinical outcomes. Anti-TNF agents are preferred for subpopulations of CD including patients with perianal CD, extraintestinal manifestations, and postoperative prevention of CD. Biosimilars have increased access to anti-TNF agents and lowered overall costs. Future studies are needed to determine which agents are most likely to be efficacious and safe for subpopulations with CD.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying and managing rare subtypes of gastrointestinal stromal tumors. 识别和管理罕见的胃肠道间质瘤亚型。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 DOI: 10.1080/17474124.2025.2486304

Leonidas Mavroeidis, Foteini Kalofonou, Ruth Casey, Andrea Napolitano, Ramesh Bulusu, Robin L Jones

{"title":"Identifying and managing rare subtypes of gastrointestinal stromal tumors.","authors":"Leonidas Mavroeidis, Foteini Kalofonou, Ruth Casey, Andrea Napolitano, Ramesh Bulusu, Robin L Jones","doi":"10.1080/17474124.2025.2486304","DOIUrl":"10.1080/17474124.2025.2486304","url":null,"abstract":"Introduction: A subset of gastrointestinal stromal tumors (GISTs) lacks the common mutations in KIT/PDGFRa genes. This is a rare and heterogeneous group of challenging GISTs due to their diversity and absence of sensitivity to the tyrosine kinase inhibitor (TKI) imatinib.Areas covered: In this manscript, we review the pathogenesis, natural history, diagnostic features and management of KIT/PDGFRa wild-type (WT) GISTs, including SDH-deficient GISTs, GISTs with mutations in the RAS/RAF pathway, and quadruple WT GISTs which lack mutations in either KIT/PDGFRa and SDH genes or components of the RAS/RAF pathway, and syndromic GISTs as well as GISTs with rare KIT/PDGFRa mutations.Expert opinion: Patients should be managed in reference centers. There has been progress in the understanding of the biology of these GISTs, and promising therapeutic targets have been identified. In SDH-deficient GISTs, the TKI olverembatinib has shown encouraging clinical activity but requires further clinical validation, while the HIF2a inhibitor bezultifan and temozolomide alone or in combination with the death receptor agonist 5 are under clinical investigation. Targeting the RAS/RAF pathway in RAS/RAF-mutated GISTs warrants evaluation in clinical trials. Rare molecular alterations in quadruple WT GISTs require investigation for their oncogenic potential. Collaborative research and patient advocacy is critical for these extremely rare tumors.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"549-561"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal transit abnormalities in irritable bowel syndrome and their relation to symptoms. 肠易激综合征胃肠道转运异常及其与症状的关系

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 Epub Date: 2025-05-01 DOI: 10.1080/17474124.2025.2493867

Abdulsalam I Aliyu, Ryo Katsumata, Hans Törnblom, Magnus Simrén

{"title":"Gastrointestinal transit abnormalities in irritable bowel syndrome and their relation to symptoms.","authors":"Abdulsalam I Aliyu, Ryo Katsumata, Hans Törnblom, Magnus Simrén","doi":"10.1080/17474124.2025.2493867","DOIUrl":"10.1080/17474124.2025.2493867","url":null,"abstract":"Introduction: Measurement of gastrointestinal (GI) transit is increasingly becoming a valuable tool in understanding the pathophysiology of symptoms of many digestive diseases, including irritable bowel syndrome (IBS). The objective of this article is to review the relevance of GI transit abnormalities for symptoms of IBS. These abnormalities relate to gastric emptying, small bowel transit, and colonic transit (whole gut transit).Areas covered: The article briefly describes the current methods of assessment, factors that influence the result of these methods and the relationship of abnormalities of GI transit with symptoms that have been reported in IBS patients. Finally, a recommendation to guide the application of transit studies in IBS in both clinical practice and research is provided.Expert opinion: Gastrointestinal transit is relevant to symptoms of bowel habits (stool frequency and form) and the relevance for other GI symptoms in IBS is not straightforward and needs further characterization. Intervention studies in IBS that incorporate objective measures of gut transit alongside symptom evaluation are warranted. Incorporating artificial intelligence into the methods of measuring transit could improve accuracy and simplify the measurements.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"447-454"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proton beam therapy in the management of hepatocellular carcinoma. 质子束治疗在肝细胞癌治疗中的应用。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 Epub Date: 2025-04-25 DOI: 10.1080/17474124.2025.2495080

Kenneth S H Chok, Tiffany Y T Joeng, Darren M C Poon

{"title":"Proton beam therapy in the management of hepatocellular carcinoma.","authors":"Kenneth S H Chok, Tiffany Y T Joeng, Darren M C Poon","doi":"10.1080/17474124.2025.2495080","DOIUrl":"10.1080/17474124.2025.2495080","url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Photon radiotherapy shows efficacy in treating HCC but carries risks of high exit dose and radiation-induced liver disease. Additionally, HCCs with portal vein tumor thrombosis (PVTT) have a poor prognosis and are associated with higher risk of death. In recent years, proton beam therapy (PBT) has emerged as a novel treatment with the ability to downstage HCC for liver transplant (LT).Areas covered: This review will provide an overview of dosimetric benefits of PBT, efficacy of PBT in treating HCC, downstaging HCC-PVTT for LT, and a comparison of PBT with other non-surgical techniques. A search of PubMed until 3 September 2024 was conducted using free search and the following keywords: hepatocellular carcinoma, proton beam therapy, portal vein tumor thrombosis, local ablative therapy, trans-arterial chemoembolization, stereotactic body radiotherapy, Y-90 radioembolization.Expert opinion: Various clinical trials using PBT have shown promising tumor local control and overall survival rates. PBT is mostly safe and efficacious for downstaging HCC-PVTT for LT. PBT has also been shown to be non-inferior to various other treatment modalities. Future research should focus on combinations of PBT with other modalities.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"495-504"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Specialized and standard nutritional formulas for the dietary management of pediatric patients with Crohn's disease: a systematic literature review. 克罗恩病儿童患者饮食管理的专业和标准营养配方：系统的文献综述。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 Epub Date: 2025-04-10 DOI: 10.1080/17474124.2025.2488887

Richard K Russell, Andrew Fagbemi, Jalil Benyacoub, Maria E Capobianco, Laura E Wells, Rita Shergill-Bonner, Preeti Sharma, Minal Patel

{"title":"Specialized and standard nutritional formulas for the dietary management of pediatric patients with Crohn's disease: a systematic literature review.","authors":"Richard K Russell, Andrew Fagbemi, Jalil Benyacoub, Maria E Capobianco, Laura E Wells, Rita Shergill-Bonner, Preeti Sharma, Minal Patel","doi":"10.1080/17474124.2025.2488887","DOIUrl":"10.1080/17474124.2025.2488887","url":null,"abstract":"Introduction: This systematic literature review (SLR) aims to compare the clinical, humanistic, and economic outcomes associated with specialized and standard nutritional formulas for the treatment of mild-to-moderate pediatric Crohn's disease.Methods: Search strategies were applied across MEDLINE, Cochrane and Web of Science (January 2000-October 2023) and recent congress proceedings (January 2021-October 2023). PRISMA-P guidelines were followed. Quality assessment evaluated risk of bias.Results: Twenty-three unique studies met the inclusion criteria. Nineteen studies (754 patients) evaluated specialized formula, 10 assessed standard formula (246 patients). Mucosal healing (7 studies), induction (20 studies) and maintenance of remission (9 studies) were reported over various timeframes. High proportions of patients who received specialized formula achieved mucosal healing (63-89% 8 weeks; 25-74% 10 weeks), and remission (50-100% 8 weeks). Specialized formula sustained remission (34-62.5% 6 months and 24-87.5% 1 year). Results were not directly comparable with standard formula due to significant heterogeneity in study methodology, patient populations, and remission definition.Conclusions: The evidence predominantly supports the benefits of specialized formula in inducing mucosal healing, remission, and sustaining positive outcomes across multiple timepoints. Direct comparison of nutritional interventions is required to further support the findings of this SLR.Protocol registration: PROSPERO CRD42023472370.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"455-465"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? 现实世界的数据告诉我们如何治疗不可切除的肝细胞癌患者？

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 Epub Date: 2025-03-10 DOI: 10.1080/17474124.2025.2476541

A Dalbeni, F Cattazzo, L A Natola, M Zoncapè, D Faccincani, B Stefanini, F Ravaioli, R Villani, A Auriemma, D Sacerdoti

{"title":"What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?","authors":"A Dalbeni, F Cattazzo, L A Natola, M Zoncapè, D Faccincani, B Stefanini, F Ravaioli, R Villani, A Auriemma, D Sacerdoti","doi":"10.1080/17474124.2025.2476541","DOIUrl":"10.1080/17474124.2025.2476541","url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) remains a major global health concern, as it is the most common primary liver cancer and the fourth leading cause of cancer-related mortality.Areas covered: Immune checkpoint inhibitors (ICIs) have significantly shifted the treatment paradigm, offering promising survival outcomes. However, the controlled conditions of randomized clinical trials (RCTs) often fail to reflect real-world complexities, emphasizing the necessity for strong real-world evidence (RWE). RWE, in most cases derived from observational studies, provides critical insights into the effectiveness, safety, and tolerability of systemic therapies across diverse populations and settings. The authors searched MEDLINE, Ovid Embase, and Scopus for full-text published articles in any language from the inception to 30 June 2024.This review evaluates RWE on systemic therapies for advanced HCC, including tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, ICIs such as nivolumab and pembrolizumab, and combination therapies like atezolizumab/bevacizumab and durvalumab/tremelimumab.Expert opinion: Studies reveal discrepancies in treatment efficacy and adverse event profiles between RCTs and routine clinical practice, underscoring the need for individualized treatment strategies. RWE highlights the influence of liver disease etiology, liver function, and tumor burden on treatment outcomes, guiding therapy selection.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"389-398"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The reliability of freely accessible, baseline, general-purpose large language model generated patient information for frequently asked questions on liver disease: a preliminary cross-sectional study. 自由获取的、基线的、通用的大型语言模型生成肝病常见问题患者信息的可靠性：一项初步横断面研究。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 Epub Date: 2025-02-27 DOI: 10.1080/17474124.2025.2471874

Madunil A Niriella, Pathum Premaratna, Mananjala Senanayake, Senerath Kodisinghe, Uditha Dassanayake, Anuradha Dassanayake, Dileepa S Ediriweera, H Janaka de Silva

{"title":"The reliability of freely accessible, baseline, general-purpose large language model generated patient information for frequently asked questions on liver disease: a preliminary cross-sectional study.","authors":"Madunil A Niriella, Pathum Premaratna, Mananjala Senanayake, Senerath Kodisinghe, Uditha Dassanayake, Anuradha Dassanayake, Dileepa S Ediriweera, H Janaka de Silva","doi":"10.1080/17474124.2025.2471874","DOIUrl":"10.1080/17474124.2025.2471874","url":null,"abstract":"Background: We assessed the use of large language models (LLMs) like ChatGPT-3.5 and Gemini against human experts as sources of patient information.Research design and methods: We compared the accuracy, completeness and quality of freely accessible, baseline, general-purpose LLM-generated responses to 20 frequently asked questions (FAQs) on liver disease, with those from two gastroenterologists, using the Kruskal-Wallis test. Three independent gastroenterologists blindly rated each response.Results: The expert and AI-generated responses displayed high mean scores across all domains, with no statistical difference between the groups for accuracy [H(2) = 0.421, p = 0.811], completeness [H(2) = 3.146, p = 0.207], or quality [H(2) = 3.350, p = 0.187]. We found no statistical difference between rank totals in accuracy [H(2) = 5.559, p = 0.062], completeness [H(2) = 0.104, p = 0.949], or quality [H(2) = 0.420, p = 0.810] between the three raters (R1, R2, R3).Conclusion: Our findings outline the potential of freely accessible, baseline, general-purpose LLMs in providing reliable answers to FAQs on liver disease.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"437-442"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thinking outside the box: unconventional artificial intelligence algorithms in the detection and management of liver cirrhosis. 跳出思维定式：肝硬化检测与管理中的非常规人工智能算法。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 Epub Date: 2025-03-27 DOI: 10.1080/17474124.2025.2483995

Ahmed Hashim, Bernardo Stefanini, Fabio Piscaglia

引用次数: 0

Transition of care in pediatric hereditary polyposis: the why, how and to whom. 儿童遗传性息肉病的过渡护理：为什么，如何和谁。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-01 DOI: 10.1080/17474124.2025.2486299

Thomas M Attard, Ajay Bansal, Caitlin E Lawson, Nicole Stoecklein, Michele H Maddux

{"title":"Transition of care in pediatric hereditary polyposis: the why, how and to whom.","authors":"Thomas M Attard, Ajay Bansal, Caitlin E Lawson, Nicole Stoecklein, Michele H Maddux","doi":"10.1080/17474124.2025.2486299","DOIUrl":"10.1080/17474124.2025.2486299","url":null,"abstract":"Introduction: Transition of care (TOC) is a process that must be planned and executed in a coordinated manner factoring patient, family, disease, and healthcare system. Among youth with gastrointestinal hereditary polyposis syndromes (HPS), poorly planned TOC can have devastating consequences from poor engagement in necessary medical care. This results in increased risk of cancer and related mortality. This review aims to emphasize unique aspects of HPS relevant to TOC, related barriers/challenges, and outline current best practice recommendations.Areas covered: A review was undertaken of transition-focused practice guidelines among youth with chronic conditions, as well as literature from major pediatric gastroenterology societies on the ideal approach for managing polyposis syndromes. Literature from PubMed and Medline, including conference abstracts and proceedings, was reviewed and in the absence of empirically supported evidence, recommendations reflect the opinion of the author experts involved in the care of adolescents and young adults (AYA) with HPS.Expert opinion: Effective TOC requires a structured, patient-centered, individualized process that includes early engagement, incremental education, and multidisciplinary collaboration. Given the unique aspects of HPS, including complex psychosocial and medical needs, there is urgent need for research toward evidence-based strategies enhancing continuity, and mitigating socio-cultural and financial barriers to care.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"527-535"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0